Iambic Therapeutics Raises $150 Million in IPO, Targets Cancer Drug

Iambic Therapeutics, a company that uses artificial intelligence to spot new medicines, announced that it has closed an initial public offering that raised $150 million. The startup sold nearly 9.4 million shares at $16 each and will begin trading on the Nasdaq under the ticker IAM. The deal will give the firm a public market presence and a new source of capital to support its research pipeline.

Since its launch in 2019, Iambic has received $462 million from private investors. Backers such as Nexus, Catalio Capital Management, Abingworth and Illumina Ventures have helped the company move its first drug candidate, a targeted cancer treatment, into early human testing. The funding round gives the startup the financial footing it needs to pursue clinical development and potentially bring a new therapy to patients.

Iambic is part of a growing wave of biotechnology firms that use AI to speed drug discovery and improve the odds of success. Many billion dollars have flowed into these young companies, and large pharmaceutical groups are beginning to adopt the technology across their operations. However, some AI‑driven drug developers have struggled after going public, and the hype around AI has raised concerns that firms might overstate what they can deliver. Iambic’s IPO filing stated that it seeks a “fundamental shift” in biopharmaceutical research, a claim that echoes the ambitious goals of other AI startups.

The company’s first drug, IAM1363, is an oral tyrosine‑kinase inhibitor designed for HER2‑positive solid tumors. Iambic says the drug’s unique structure could make it highly selective while covering a broad range of HER2 variants, potentially treating breast and lung cancers driven by HER2. Early results from a Phase 1 study showed clinical anti‑tumor activity and a favorable safety profile in patients who had tried multiple prior treatments. A registration trial could begin as early as 2027, according to the company’s regulatory filings.

In addition to IAM1363, Iambic is advancing IAM217, which targets the KIF18A protein for ovarian, triple‑negative breast and other solid tumors, and a third candidate that targets CDK2 and CDK4 for a common breast cancer type. The company has attracted interest from large drugmakers such as Takeda and AbbVie, as well as biotechs Jazz Pharmaceuticals and Revolution Medicines. Twenty‑five biotech companies priced IPOs in 2026, a sharp rise from the modest pace of the previous year, and more firms such as Aspen Neuroscience and Lycia Therapeutics may join the public markets later this year.